ADCendo Stock

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

Sign up today and learn more about ADCendo Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About ADCendo Stock

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

Funding History

August 2019$10.0M
April 2021$51.0M
April 2023$31.0M

Management

Co-founder

Niels Behrendt

Chief Scientific Officer

Dominik Mumberg

CFO

Henrik Stage

Co-founder & CEO

Henrik Stage

Board Member

Sanne de Jongh

Advisor

John Lambert

Board Member

Marten Steen

Advisor

Vincent F.M.H. de Groot

Board Member

Joel Jean Mairet

Board Member

Lars H. Engelholm

Co-founder

Lars H. Engelholm

Co-founder & COO

Christoffer Nielsen

Board Member

Jeroen Bakker

Board Member

Ohad Hammer

Board Member

Reza Halse

Chairman of the Board

John Haurum

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo